Mesoblast has reported impressive efficacy data from the first cohort of the Phase II trial of its mesenchymal precursor cell (MPC) product in rheumatoid arthritis (RA), ahead of full results due in Q316. Key catalysts next quarter will be the first interim analysis from the pivotal MPC-150-IM heart failure trial, together with an update to trial timelines following the halving of the trial to 600 patients. The launch of Temcell in Japan for graft vs host disease this quarter will bring a roy
18 Feb 2016
Impressive signs of efficacy in rheumatoid arthritis
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Impressive signs of efficacy in rheumatoid arthritis
Mesoblast Limited (MSB:ASX) | 0 0 -2.3% | Mkt Cap: 591.5m
- Published:
18 Feb 2016 -
Author:
Katherine Genis -
Pages:
3
Mesoblast has reported impressive efficacy data from the first cohort of the Phase II trial of its mesenchymal precursor cell (MPC) product in rheumatoid arthritis (RA), ahead of full results due in Q316. Key catalysts next quarter will be the first interim analysis from the pivotal MPC-150-IM heart failure trial, together with an update to trial timelines following the halving of the trial to 600 patients. The launch of Temcell in Japan for graft vs host disease this quarter will bring a roy